SCHEMBL4707155

SCHEMBL4707155

O=C(CC(=O)c1nnn(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c1-c1cccnc1)c1ccccc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 1/20 0.53
KDR P35968 2/20 0.39
GRM2 Q14416 1/20 0.38
CRHR1 P34998 1/20 0.38
GAA P10253 2/20 0.37
ALDH1A1 P00352 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CYP19A1 P11511 1/20 0.37
TSHR P16473 1/20 0.37
MAPT P10636 1/20 0.37
SLC2A1 P11166 1/20 0.37
SLC2A3 P11169 1/20 0.37
SLC2A4 P14672 1/20 0.37
ADORA3 P0DMS8 2/20 0.36
NR3C1 P04150 1/20 0.36
P2RX7 Q99572 1/20 0.36
SRPK1 Q96SB4 1/20 0.36
GPBAR1 Q8TDU6 1/20 0.36
HTT P42858 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4706605 0.86 IDH1 (0.49) IDH1KDRGRM2CRHR1GAA
SCHEMBL4706658 0.85 IDH1 (0.62) IDH1GAAALDH1A1SMN1; SMN2TSHR
SCHEMBL4707915 0.83 IDH1 (0.48) IDH1KDRGRM2GAAALDH1A1
SCHEMBL4638481 0.83 IDH1 (0.44) IDH1KDRGRM2CRHR1GAA
SCHEMBL4637742 0.82 ALDH1A1 (0.52) IDH1KDRGAAALDH1A1CYP19A1
SCHEMBL4706229 0.81 IDH1 (0.44) IDH1KDRGRM2CRHR1SMN1; SMN2
SCHEMBL4637999 0.81 IDH1 (0.46) IDH1KDRGAAALDH1A1SMN1; SMN2
SCHEMBL4707863 0.81 IDH1 (0.44) IDH1GRM2CRHR1GPBAR1
SCHEMBL4705371 0.80 IDH1 (0.43) IDH1KDRGRM2CRHR1GAA
SCHEMBL4639448 0.80 IDH1 (0.49) IDH1GRM2CRHR1ALDH1A1CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7320994-B2 Triazole derivatives as tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2008-01-22 US disclosed
EP-1501809-B1 TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-01-16 EP disclosed
US-20050239786-A1 Triazole derivatives as tachykinin receptor antagonists ELI LILLY COMPANY (US) 2005-10-27 US disclosed
EP-1501809-A1 TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-02-02 EP disclosed
WO-2003091226-A1 TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239786-A1 Triazole derivatives as tachykinin receptor antagonists TACR1, TACR2, BDKRB1 IDH1 1082/4885KDR 600/4885GRM2 2864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.